Nissay Asset Management Corp Japan Has $11.88 Million Stake in Alnylam Pharmaceuticals, Inc. $ALNY

Nissay Asset Management Corp Japan raised its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 7.0% in the second quarter, HoldingsChannel.com reports. The firm owned 39,482 shares of the biopharmaceutical company’s stock after purchasing an additional 2,584 shares during the quarter. Nissay Asset Management Corp Japan’s holdings in Alnylam Pharmaceuticals were worth $11,885,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Geode Capital Management LLC increased its holdings in shares of Alnylam Pharmaceuticals by 6.1% during the fourth quarter. Geode Capital Management LLC now owns 2,650,722 shares of the biopharmaceutical company’s stock worth $1,056,884,000 after purchasing an additional 151,480 shares during the period. Norges Bank bought a new stake in shares of Alnylam Pharmaceuticals in the fourth quarter valued at approximately $895,816,000. Orbis Allan Gray Ltd boosted its stake in shares of Alnylam Pharmaceuticals by 29.8% in the second quarter. Orbis Allan Gray Ltd now owns 2,121,412 shares of the biopharmaceutical company’s stock valued at $691,771,000 after buying an additional 486,489 shares during the period. Wellington Management Group LLP grew its position in Alnylam Pharmaceuticals by 9.0% during the second quarter. Wellington Management Group LLP now owns 2,110,407 shares of the biopharmaceutical company’s stock worth $635,296,000 after buying an additional 174,482 shares in the last quarter. Finally, Legal & General Group Plc grew its position in Alnylam Pharmaceuticals by 8.3% during the fourth quarter. Legal & General Group Plc now owns 961,496 shares of the biopharmaceutical company’s stock worth $382,339,000 after buying an additional 73,716 shares in the last quarter. Institutional investors and hedge funds own 92.97% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have commented on ALNY. Oppenheimer lowered their price objective on Alnylam Pharmaceuticals from $500.00 to $350.00 and set an “outperform” rating on the stock in a research note on Friday, July 31st. Weiss Ratings raised Alnylam Pharmaceuticals from a “hold (c-)” rating to a “hold (c)” rating in a report on Friday, July 31st. Truist Financial decreased their price target on Alnylam Pharmaceuticals from $410.00 to $315.00 and set a “buy” rating on the stock in a research report on Tuesday, August 4th. Citigroup dropped their price target on Alnylam Pharmaceuticals from $380.00 to $340.00 and set a “buy” rating for the company in a research note on Monday, August 3rd. Finally, Royal Bank Of Canada cut their price objective on shares of Alnylam Pharmaceuticals from $445.00 to $350.00 and set an “outperform” rating for the company in a research report on Friday, July 31st. Three research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and five have given a Hold rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $386.14.

Insider Activity

In related news, Director David E. I. Pyott sold 3,830 shares of the company’s stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $299.18, for a total transaction of $1,145,859.40. Following the completion of the transaction, the director directly owned 1,582 shares in the company, valued at $473,302.76. This represents a 70.77% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 0.86% of the company’s stock.

Alnylam Pharmaceuticals Stock Performance

Alnylam Pharmaceuticals stock opened at $237.10 on Friday. Alnylam Pharmaceuticals, Inc. has a 12-month low of $197.81 and a 12-month high of $495.55. The company has a quick ratio of 2.99, a current ratio of 3.05 and a debt-to-equity ratio of 0.75. The business’s 50-day moving average price is $262.62 and its two-hundred day moving average price is $293.73. The stock has a market cap of $31.73 billion, a PE ratio of 44.07 and a beta of 0.30.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Thursday, July 30th. The biopharmaceutical company reported $1.84 EPS for the quarter, topping the consensus estimate of $1.63 by $0.21. The firm had revenue of $1.29 billion during the quarter, compared to the consensus estimate of $1.32 billion. Alnylam Pharmaceuticals had a return on equity of 84.93% and a net margin of 15.26%.The business’s quarterly revenue was up 66.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.51) earnings per share. As a group, analysts expect that Alnylam Pharmaceuticals, Inc. will post 6.59 earnings per share for the current fiscal year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.